|1.||Choudhary, Vivek: 1 article (01/2015)|
|2.||Patel, Ravi: 1 article (01/2015)|
|3.||Bollag, Wendy B: 1 article (01/2015)|
|4.||Karempelis, Peter: 1 article (01/2015)|
|5.||Kaddour-Djebbar, Ismail: 1 article (01/2015)|
|6.||Helwa, Inas: 1 article (01/2015)|
|7.||Smith, Sylvia B: 1 article (08/2014)|
|8.||Makala, Levi: 1 article (08/2014)|
|9.||Pace, Betty S: 1 article (08/2014)|
|10.||Singh, Nagendra: 1 article (08/2014)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
10/01/1997 - "Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?"
09/01/1996 - "Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate."
02/01/2006 - "Fumaric acid esters (FAE) are effective against psoriasis vulgaris and monomethylfumarate (MMF) is believed to be the most bioactive metabolite of this medication. "
01/01/2015 - "Monomethylfumarate (MMF) is thought to be the bioactive ingredient of the drug Fumaderm (Biogen Idec, Cambridge, MA), licensed in Germany since 1994 for the treatment of moderate-to-severe psoriasis. "
10/31/2008 - "Monomethylfumarate is the active metabolite of the psoriasis drug Fumaderm. "
08/01/2014 - "The present study evaluated (1) the retinal pigment epithelial (RPE) cell as a hemoglobin producer and novel cellular target for fetal hemoglobin (HbF) induction, and (2) monomethylfumarate (MMF) as an HbF-inducing therapy and abrogator of oxidative stress and inflammation in SCD retina. "
01/01/1978 - "Both exhibited at least two attacks of severe ketoacidosis, during which they excreted, in addition to methylmalonic acid, a number of abnormal compounds: 3-hydroxypropionic acid, 2-methyl-3-hydroxybutyric, 3-hydroxy-n-valeric acid, 3-oxo-n-valeric acid, 2-methyl-3-oxobutyric acid, citraconic acid and N-tiglyglycine. "
|4.||Fetal Hemoglobin (Hemoglobin F)
|8.||Niacin (Nicotinic Acid)